about the author

Zachary Brennan

Senior Editor

zachary@endpointsnews.com @ZacharyBrennan
Zachary Brennan on LinkedIn

Zachary Brennan is senior editor for Endpoints, covering the US regulatory agency and others around the globe. He previously wrote about the FDA, Covid-19, and the biopharma industry for POLITICO, and was managing editor for the Regulatory Affairs Professionals Society's news publication. A DC-area native, he majored in English at Northwestern University.

author articles

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

13 hours ago
Pharma
FDA+

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

15 hours ago
AI
FDA+

Ahead of ad­comm, FDA rais­es safe­ty ques­tions for As­traZeneca’s re­ver­sal agent for life-threat­en­ing bleeds

Yesterday
Pharma
FDA+

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

2 days ago
Cell/Gene Tx
FDA+

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

6 days ago
People
Pharma

Louisiana's Bill Cas­sidy named next chair of Sen­ate health com­mit­tee

6 days ago
Pharma
Law

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

6 days ago
Manufacturing

Drug in­spec­tor at­tri­tion leads to 'many few­er' checks than 2016 peak, GAO says

Last week
FDA+
Manufacturing

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Last week
FDA+

FDA records re­quest lands Chi­nese API man­u­fac­tur­er on blocked im­port list

Last week
Pharma
FDA+

FDA seeks to pull OTC nasal de­con­ges­tant in­gre­di­ent due to lack of ef­fi­ca­cy

Last week
Pharma
FDA+

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

2 weeks ago
FDA+
Law

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

3 weeks ago
Pharma
FDA+

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

3 weeks ago
FDA+

FDA ex­pands faster drug re­view pi­lot from sup­ple­men­tal to full ap­pli­ca­tions

3 weeks ago
Pharma
FDA+

BMS, J&J and As­traZeneca plea with ap­peals court to over­turn drug price ne­go­ti­a­tions

3 weeks ago
Pharma
Law

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

3 weeks ago
FDA+

Fed­er­al court backs FDA's ap­proval of com­peti­tor to Jaz­z's sleep drug

3 weeks ago
Pharma
FDA+

FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able

3 weeks ago
FDA+

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

4 weeks ago
FDA+
Manufacturing

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

4 weeks ago
Pharma
FDA+

Lex­i­con's once-re­ject­ed di­a­betes drug is ques­tioned again by FDA ahead of ad­comm

4 weeks ago
Pharma
FDA+

Bi­par­ti­san let­ter ques­tions FDA's 'nar­row' in­ter­pre­ta­tion for pri­or­i­ty re­view vouch­ers

4 weeks ago
Pharma
FDA+

Hun­gary's Olivér Várhe­lyi read­ies to be EU health com­mis­sion­er, pledg­ing ma­jor phar­ma sup­port

4 weeks ago
Pharma
Law
1234 Next page Last page
A service from the Financial Times